XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Other Agreements
3 Months Ended
Mar. 31, 2021
Other Agreements [Abstract]  
Other Agreements

Note 10. Other Agreements

NuvoGen Obligation

Pursuant to the Company’s asset purchase agreement with NuvoGen Research, LLC (“NuvoGen”), as amended, the Company is obligated to pay NuvoGen the greater of $400,000 or 6% of annual revenue until the obligation is paid in full. In addition to fixed quarterly payments of $100,000, there were no revenue-based payments payable as of March 31, 2021 compared to approximately $54,777 of revenue-based payments payable December 31, 2020. There have been no significant modifications to the terms and conditions of the Company’s NuvoGen obligation since the disclosures made in Part II, Item 8, Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 25, 2021.

 

Remaining minimum payments to be made in 2021 include an estimate of additional revenue-based payments to be made in 2021 relating to actual revenue generated in the second and third quarters of 2021, estimated using actual revenue generated in the same quarters in 2020. Minimum payments for 2022 include an estimate of additional revenue-based payments to be made in 2022 relating to actual revenue generated in the fourth quarter of 2021, estimated using actual revenue generated in the same quarter in 2020. Remaining minimum payments include only the minimum quarterly payments to be made in each period. Actual payments could vary from what is shown in the table, to the extent that 6% of the Company’s annual revenue in 2021 and beyond exceeds $400,000.

 

The remaining minimum payments to be made to NuvoGen as of March 31, 2021 are as follows for each fiscal year:

 

2021

 

$

324,424

 

2022

 

 

454,980

 

2023

 

 

400,000

 

2024

 

 

400,000

 

2025

 

 

400,000

 

2026 and beyond

 

 

2,778,568

 

Total NuvoGen obligation payments

 

 

4,757,972

 

Plus interest accretion

 

 

76,270

 

Total NuvoGen obligation, net

 

$

4,834,242

 

 

The Company has recorded the obligation at the estimated present value of the future payments using a discount rate of 2.5%, the Company’s estimate of its effective borrowing rate for similar obligations. The unamortized interest accretion was $(76,270) and $(79,376) at March 31, 2021 and December 31, 2020, respectively. Discount accreted during the three months ended March 31, 2021 and 2020 was $(3,106) and $(3,430), respectively.